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The anti-inflammatory, antifibrotic, and antiproteinuric
properties of vitamin D have been defined in studies using
active vitamin D analogs. In this prospective observational
study we determined whether nutritional vitamin D repletion
can have additional beneficial effects in patients with
type 2 diabetic nephropathy already established on
renin–angiotensin–aldosterone system inhibition. During
a 7-month period, 63 patients were enrolled and those with
low levels of 25(OH)D were treated with oral cholecalciferol
for 4 months. Baseline serum 25(OH)D and 1,25(OH)2D
showed no significant correlation with baseline urinary
MCP-1, TGF-b1, or albuminuria measured as the urinary
albumin-to-creatinine ratio. Of the 63 patients, 54 had
insufficient or deficient levels of serum 25(OH)D and 49
complied with cholecalciferol therapy and follow-up. Both
25(OH)D and 1,25(OH)2D were significantly increased at 2
and 4 months of treatment. Albuminuria and urinary TGF-b1
decreased significantly at both time points compared to
their baseline values, while urinary MCP-1 did not change.
Thus, in the short term, dietary vitamin D repletion with
cholecalciferol had a beneficial effect in delaying the
progression of diabetic nephropathy above that due to
established renin–angiotensin–aldosterone system inhibition.
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Diabetic nephropathy (DN) has become the most frequent
cause of end-stage renal disease requiring dialysis and/or
renal transplantation in developed countries.1,2 Even with
established conventional therapy for glycemic and blood
pressure control, and the use of inhibitors of the renin–
angiotensin–aldosterone system (RAAS), a significant pro-
portion of diabetic patients develop chronic kidney disease
(CKD) and progress to end-stage renal disease,3 indicating
a need for additional treatments.
Growing evidence indicates that vitamin D may have
antiproteinuric and renoprotective effects in patients with
CKD including DN. Prevalence of vitamin D deficiency
and insufficiency, defined by most experts as a serum
25-hydroxyvitamin D (25(OH)D) level of o20 ng/ml
(50 nmol/l) and 21–29 ng/ml (52–72 nmol/l), respectively,4 is
higher in CKD patients than in the general population,
especially in patients with severe renal impairment.5 In
addition, the levels of 25(OH)D, 1,25-dihydroxyvitamin D
(1,25(OH)2D), and 24,25(OH)2D were significantly lower in
diabetic CKD patients compared with nondiabetic CKD
patients.6 In the NHANES III (Third National Health and
Nutrition Examination Survey) cohort, vitamin D deficiency
was associated with an increased risk of albuminuria.7
A prospective study of 168 patients with CKD stage 2–5 of
various etiologies showed that plasma 25(OH)D is an inverse
predictor of CKD progression and death.8 Another multi-
variable regression analysis of CKD patients showed that
lower calcitriol concentrations strongly correlated with
higher urinary albumin-to-creatinine ratio (uACR) and
lower estimated glomerular filtration rate (eGFR).9 In several
randomized clinical trials in patients with CKD of various
etiologies, a selective activator of vitamin D receptor (VDR),
paricalcitol, reduced proteinuria and high-sensitivity
C-reactive protein.10–12 An uncontrolled trial in patients
with IgA nephropathy on RAAS inhibition also showed a
significant decrease of proteinuria and serum transforming
growth factor-b (TGF-b) upon treatment with calcitriol.13
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Finally, the recently published VITAL (Selective Vitamin D
Receptor Activator (Paricalcitol) for Albuminuria Lowering)
study demonstrated an antiproteinuric effect of pari-
calcitol in type 2 diabetic patients treated with RAAS inhibition.14
Along with albuminuria, which is widely accepted as a
major progression marker for both diabetic and nondiabetic
CKD,15,16 inflammatory and profibrotic cytokines such as
monocyte chemoattractant protein-1 (MCP-1) and TGF-b
have been shown to play an important role in the pathogenesis
of DN in a mouse model of type 2 diabetes mellitus.17,18
Previous data from in vitro and in vivo studies suggest that
active vitamin D and its analogs reduce the expression of these
cytokines and ameliorate the renal injury.19–25
Taken together, the above data suggest a therapeutic
potential of vitamin D to delay the progression of DN.
However, there has been no study, especially in patients
on established RAAS inhibition, investigating the effects of
nutritional vitamin D repletion on the progression markers
of DN. Nutritional vitamin D has several advantages over
active vitamin D analogs; it is cheaper and is safer in terms
of mineral metabolism, and therefore frequent monitoring
is not required. Also, the current Kidney Disease Outcomes
Quality Initiative (KDOQI) guidelines recommend the reple-
tion of 25(OH)D before the treatment with active vitamin D
analogs in CKD stage 3 and 4.26 In this prospective study,
we therefore performed vitamin D repletion using chole-
calciferol in type 2 diabetic patients with CKD and vitamin D
deficiency/insufficiency on established RAAS inhibition, in an
unchanged daily clinical setting, and investigated its impact on
albuminuria and urinary cytokines MCP-1 and TGF-b1.
RESULTS
Baseline data
A total of 196 patients were evaluated consecutively and 63
patients were enrolled during a 7-month period. The patient
disposition is summarized in Figure 1. Baseline character-
istics of the patients are shown in Table 1. Most patients had a
long history of diabetes of 410 years, and 55% of the
patients were on insulin therapy. In all, 5 patients had biopsy-
proven diagnosis of DN and 29 patients had documented
diabetic retinopathy. The mean values of serum 25(OH)D
and 1,25(OH)2D were 18.4±9.8 ng/ml and 23.9±13.8 pg/ml,
respectively. Of 63 patients, 54 (86%) had insufficient
(n¼ 25; 40%) or deficient levels (n¼ 29; 46%) of serum
25(OH)D (Figure 1).
Correlations of vitamin D concentrations and urinary MCP-1,
TGF-b1, and uACR
Urinary MCP-1/creatinine ratio, urinary TGF-b1/creatinine
ratio, and uACR showed a log-normal distribution. Baseline
serum 25(OH)D and 1,25(OH)2D showed no significant
correlation with urinary MCP-1/creatinine ratio, urinary
TGF-b1/creatinine ratio, or uACR. There was a weak positive
correlation of uACR with urinary MCP-1/creatinine ratio
(Pearson’s R¼ 0.3119, P¼ 0.0128), but not with urinary
TGF-b1/creatinine ratio (Figure 2).
Longitudinal follow-up results over 4 months
Of the 54 patients with insufficient/deficient baseline levels of
serum 25(OH)D, 49 patients (91%) complied with treatment
and were monitored at 2 and 4 months (Figure 1). One
patient did not take the medication properly and 4 patients
did not keep the follow-up appointments. No adverse events
were observed throughout the follow-up period. One patient
was diagnosed of gastric cancer at 3 months during follow-up
and died while receiving chemotherapy. The results are
summarized in Table 2.
Vitamin D and vitamin D binding protein
Although the patients were treated with different regimens,
based on the baseline 25(OH)D level, all patients showed a
significant increase of both 25(OH)D and 1,25(OH)2D
(Po0.0001 for 25(OH)D in patients with both 25(OH)D
deficiency and insufficiency at 2 and 4 months; Po0.0001 for
1,25(OH)2D at 2 months in patients with both 25(OH)D
deficiency and insufficiency; P¼ 0.0057 at 4 months in
patients with 25(OH)D deficiency; and P¼ 0.0015 in patients
with 25(OH)D insufficiency; Table 2 and Figure 3). Out of
49 patients, 40 (82%) achieved replete status of 25(OH)D
(X30 ng/ml) at 2 months and 38 patients (78%) at 4 months.
The increase of 25(OH)D was significant in all patients
regardless of CKD stage. Although the increase of
1,25(OH)2D at 2 months was significant in all patients, only
patients with CKD stage 3 showed a significant increase at
4 months (Table 2).
There was a strong positive correlation between urinary
vitamin D binding protein/creatinine ratio (uVDBPCR) and
Enrollment
n = 63
Assessed for eligibility
n = 196
Cholecalciferol treatment
n = 26
(3 excluded due to
lack of compliance)
n = 49 n = 8
n = 23
(2 excluded due to
lack of compliance)
n = 8
(1 excluded due to
lack of compliance)
No
Deficient
n = 29
Insufficient
n = 25
Sufficient
n = 9
25(OH)D
Treatment
Follow-up
Analyzed
Excluded (n = 133)
• Treatment with vit D analogs (n = 52)
• CKD stage 5 (n = 33)
• Other exclusion criteria (n = 36)
• Refused to participate (n =12)
Screening
Figure 1 | Flow diagram showing recruitment and follow-up of
patients. CKD, chronic kidney disease; 25(OH)D, 25-hydroxy-
vitamin D.
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uACR throughout the follow-up period (Pearson’s R¼ 0.8720,
Po0.0001 at baseline; Pearson’s R¼ 0.8289, Po0.0001 at
2 months; and Pearson’s R¼ 0.8170, Po0.0001 at 4 months).
At 2- and 4-month follow-up, uVDBPCR showed a trend
toward a reduction compared with baseline level, although it
did not reach statistical significance (P¼ 0.1614 at 2 months;
P¼ 0.3817 at 4 months). Plasma VDBP increased at 2
(P¼ 0.0280) and 4 months (P¼ 0.0520; Table 2).
Proteinuria
uACR decreased from (geometric mean with 95% confidence
interval) 16.4 mg/mmol (9.7–27.4) to 12.2 mg/mmol (7.1–20.7)
at 2 months (P¼ 0.0011) and 12 mg/mmol (7.0–20.8) at 4
months (P¼ 0.0201 vs baseline; Table 2 and Figure 4a). As the
antihypertensive medications were increased in 9 patients
during the follow-up, we also analyzed the changes of uACR in
40 patients who had no changes of antihypertensive medica-
tions. The uACR decreased from 12.7 mg/mmol (7.3–22.3)
to 9.9 mg/mmol (5.5–17.9) at 2 months (P¼ 0.0141) and to
9.4 mg/mmol (5.2–17) at 4 months (P¼ 0.0603; Figure 4b).
Urinary TGF-b1 and MCP-1
Urinary TGF-b1/creatinine ratio decreased significantly at 2
and 4 months (from 26.5 ng/mmol (20.3–34.4) to 15.5 ng/
mmol (10.7–22.4; P¼ 0.0095) at 2 months and 9.5 ng/mmol
(6.0–14.8; Po0.0001) at 4 months; Table 2 and Figure 5a).
In the 40 patients who had no changes of antihypertensive
medications, urinary TGF-b1/creatinine ratio also showed
a significant reduction at both follow-up time points
(from 27.5 ng/mmol (20.6–36.8) to 17.4 ng/mmol (11.7–25.9;
P¼ 0.0315) at 2 months and 11.2 ng/mmol (6.9–18.3;
P¼ 0.0012) at 4 months; Figure 5b). No significant changes
of urinary MCP-1/creatinine ratio were observed at either
follow-up time point (P¼ 0.1799 at 2 months and P¼ 0.4916
at 4 months; Figure 5c). The same was true for the patients who
had no changes of antihypertensive medications (Figure 5d).
Blood pressure
No significant changes of systolic and diastolic blood pressure
(BP) were observed during the course of follow-up. In
9 patients, antihypertensive medications were changed: newly
started or increased diuretics in 4 patients, angiotensin
receptor blocker in 1 patient, angiotensin-converting enzyme
inhibitor in 2 patients, calcium antagonist in 3 patients, and
a-blocker in 1 patient.
Other laboratory parameters
Renal function did not change significantly throughout the
follow-up period, and there were no significant changes of
corrected serum calcium, phosphate, intact parathyroid
hormone, or glycosylated hemoglobin (HbA1c). Spot urine
calcium/creatinine ratio did not show any significant changes
throughout the follow-up period (Table 2).
Evolution of vitamin D, uACR, urinary TGF-b1, and MCP-1 in
smokers vs nonsmokers
At the enrollment, smokers (21 out of 63 patients; 33%) had
significantly lower levels of 1,25(OH)2D compared with
nonsmokers (16.3±8.3 vs 27.7±14.5 pg/ml; P¼ 0.0020),
whereas the levels of 25(OH)D did not differ between two
Table 1 | Baseline patient characteristics
Patients (n=63)
Age 69±9.6
Men (%) 48 (76%)
Ethnicity (%)
Caucasian 27 (43%)
African/Caribbean 4 (6%)/10 (16%)
Indoasian/Asian 14 (22%)/8 (13%)
Duration of diabetes mellitus (years) 17±8.8
Insulin therapy 35 (55%)
HbA1c (%) 7.7±1.3
Comorbidities (%)
Hypertension 59 (94%)
Coronary artery disease 21 (33%)
Cerebrovascular disease 8 (13%)
Peripheral vascular disease 5 (8%)
Current smoker (%) 21 (33%)
BMI (kg/m2) 32±6.5
Blood pressure (mmHg)
Systolic 130±18
Diastolic 69±10
RAAS inhibition (%) 63 (100%)
ACE inhibitor only 25 (39%)
ARB only 20 (32%)
ACE inhibitor+ARB 15 (24%)
ARB+direct renin inhibitor 3 (5%)
Statin (%) 56 (89%)
Antiplatelet agent or anticoagulant (%) 54 (86%)
25-Hydroxyvitamin D (ng/ml) 18.4±9.8
1,25 Dihydroxyvitamin D (pg/ml) 23.9±13.8
Plasma vitamin D binding protein (mg/dl) 25.9±13.4
Urinary vitamin D binding protein/creatinine
ratio (mg/mmol)
Geometric mean (95% CI) 20.2 (12.3–33.1)
Median (IQR) 15.2 (4.6–86.4)
eGFR (MDRD, ml/min per 1.73m2) 42±14.7
60–89 9 (14%)
30–59 44 (70 %)
15–29 10 (16%)
Serum albumin (g/l) 37.4±3.5
Serum calcium corrected for albumin (mg/dl) 9.5±0.4
Serum phosphate (mg/dl) 3.6±0.7
Intact parathyroid hormone (pmol/l) 10.3±7.1
Spot urine calcium/creatinine ratio
Geometric mean (95% CI) 0.08 (0.06–0.11)
Median (IQR) 0.07 (0.03–0.23)
Spot urine albumin/creatinine ratio (mg/mmol)
Geometric mean (95% CI) 15.9 (10.4–24.4)
Median (IQR) 13 (4–80.7)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; HbA1c, glycosylated hemoglobin; IQR, interquartile range; MDRD,
Modification of Diet in Renal Disease; RAAS, renin–angiotensin–aldosterone system.
If not indicated otherwise, results are presented as mean±s.d. Skewed values are
presented as geometric mean with 95% CI and median and IQR.
Conversion factors for units: calcium in mg/dl to mmol/l,  0.2495; phosphorus in
mg/dl to mmol/l,  3.968; creatinine in mg/dl to mmol/l,  88.4; 25-hydroxyvitamin
D in ng/ml to nmol/l,  2.496; 1,25-hydroxyvitamin D in pg/ml to pmol/l,  2.6.
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Figure 2 |Correlation analysis of baseline albuminuria and urinary cytokines. Correlation of baseline urinary albumin-to-creatinine ratio
(uACR) with (a) urinary monocyte chemoattractant protein-1 (MCP)-1/creatinine ratio (Pearson’s R¼ 0.3119, P¼ 0.0128) and (b) transforming
growth factor-b1 (TGF-b1)/creatinine ratio (Pearson’s R¼ –0.1205, P¼ 0.3468).
Table 2 | Summary of follow-up results
Baseline (n=49) Month 2 (n=49) Month 4 (n=48)
25(OH)D (ng/ml) 15.6±7.0 41.2±11.4* 39.7±12.8*
eGFR (ml/min per 1.73m2)
60–89 (n=7) 13.3±7.7 46.6±12.9# 42.7±9.7**
30–59 (n=34) 15.8±7.2 39.9±11.9* 39.8±14.4*
15–29 (n=8) 16.7±5.2 41.9±6.6** 36.6±7.5**
1,25(OH)2D (pg/ml) 24.2±14.4 51.0±16.0* 42.8±23.8*
eGFR (ml/min per 1.73m2)
60–89 (n=7) 26.8±19.0 59.3±20.5** 47.8±27.2
30–59 (n=34) 23.6±13.8 50.1±15.6* 46.1±36.2#
15–29 (n=8) 24.2±14.0 45.6±13.2## 46.4±34.5
Spot urine albumin/creatinine ratio (mg/mmol)
Geometric mean (95% CI) 16.4 (9.7–27.4) 12.2 (7.1–20.7)# 12.0 (7.0–20.8)##
Median (IQR) 13.2 (3.9–89.5) 10.7 (3.3–53.9) 11.5 (3.2–45.8)
Urinary TGF-b1/creatinine ratio (ng/mmol)
Geometric mean (95% CI) 26.5 (20.3–34.4) 15.5 (10.7–22.4)# 9.5 (6.0–14.8)*
Median (IQR) 33.7 (16.6–52) 17.1 (8.9–39.5) 12.1 (2.9–30.4)
Urinary MCP-1/creatinine ratio (ng/mmol)
Geometric mean (95% CI) 10.4 (7.8–13.9) 12.7 (10.1–16.0) 11.9 (8.3–17.0)
Median (IQR) 10.4 (6.4–21.4) 12.5 (7.5–19.8) 12.8 (8.6–23.5)
eGFR (ml/min per 1.73 m2) 42±15.2 41±16.0 40±15.4
Serum calcium corrected for albumin (mg/dl) 9.5±0.4 9.4±0.4 9.4±0.5
Serum phosphate (mg/dl) 3.5±0.7 3.5±0.6 3.5±0.8
iPTH (pmol/l) 10.5±7.1 9.6±7.6 10.0±8.4
HbA1c (%) 7.8±1.7 7.7±1.8 7.9±1.9
Plasma VDBP (mg/dl) 27.3±13.7 29.2±16.4## 30.4±16.3
Urinary VDBPCR (mg/mmol)
Geometric mean (95% CI) 23.4 (13.3–41.2) 18.9 (11.1–32.2) 19.4 (11.4–32.9)
Median (IQR) 14.3 (5.7–135.2) 10.2 (5.1–72.3) 14.9 (5.5–115.2)
Spot urine calcium/creatinine ratio
Geometric mean (95% CI) 0.08 (0.06–0.1) 0.09 (0.06–0.12) 0.08 (0.06–0.11)
Median (IQR) 0.05 (0.03–0.23) 0.09 (0.04–0.21) 0.07 (0.03–0.22)
Blood pressure (mmHg)
Systolic 129±16 131±18 130±15
Diastolic 69±11 68±11 67±9
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; IQR, interquartile range; iPTH, intact parathyroid hormone;
MCP-1, monocyte chemoattractant protein-1; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; TGF-b1, transforming growth factor-b1; VDBP, vitamin D
binding protein; VDBPCR, vitamin D binding protein/creatinine ratio.
*P vs baseline o0.0001; **P vs baseline o0.001; #P vs baseline o0.01; ##P vs baseline o0.05.
Skewed values are presented as geometric mean with 95% CI and median and IQR. If not indicated otherwise, results are presented as mean±s.d.
854 Kidney International (2011) 80, 851–860
or ig ina l a r t i c l e MJ Kim et al.: Oral cholecalciferol in type 2 diabetic nephropathy
groups (19.4±10.2 vs 17.9±9.7 ng/ml; P¼ 0.6459). The
evolution of 25(OH)D, 1,25(OH)2D, uACR, urinary TGF-b1/
creatinine ratio, and MCP-1/creatinine ratio in smokers vs
nonsmokers is summarized in Table 3.
Patients with sufficient baseline 25(OH)D levels
Of the nine patients with sufficient baseline serum 25(OH)D,
eight patients were monitored at 4 months. There were
no significant changes of 25(OH)D, 1,25(OH)2D, uACR,
urinary MCP-1/creatinine ratio, or urinary TGF-b1/creati-
nine ratio.
DISCUSSION
We performed a prospective uncontrolled observational
study to investigate the impact of vitamin D repletion using
nutritional vitamin D, cholecalciferol, on albuminuria and
urinary cytokines in type 2 diabetic patients with CKD on
RAAS inhibition. Although there have been several clinical
trials showing the antiproteinuric effect of active vitamin D
analogs,10–14 this is the first study, to our knowledge,
examining the effects of nutritional vitamin D supplementa-
tion in addition to RAAS inhibition on albuminuria and
urinary cytokines in patients with DN.
The analysis of 63 patients at enrollment showed
no significant correlations between vitamin D (25(OH)D
or 1,25(OH)2D) and uACR, urinary MCP-1/creatinine ratio,
or urinary TGF-b1/creatinine ratio. These results are not
consistent with some previous studies showing an inverse
correlation between urinary MCP-1 and serum 1,25(OH)2D,
27
and between albuminuria and serum 25(OH)D.7 This inconsis-
tency might be because of the lower number of patients in our
study and/or differences in the patient populations studied.
The RAAS inhibition in our patients may also have played a
role in this difference, as angiotensin II receptor blocker has
been shown to block mRNA expression of MCP-1 (ref. 28)
in vitro and TGF-b1 (ref. 29) in vivo. The levels of uACR
and urinary cytokines may therefore have been relatively
suppressed in our patients. The positive correlation between
uACR and urinary MCP-1 was consistent with our previous
study, showing higher MCP-1 levels in diabetic patients with
macroalbuminuria than in normo- or micro-albuminuric
patients.30
The longitudinal follow-up data demonstrated that
cholecalciferol therapy led to a significant increase of both
25(OH)D and 1,25(OH)2D, suggesting the effective conver-
sion of 25(OH)D to 1,25(OH)2D. There was a trend toward
a reduction in both values at 4 months compared with
2 months of follow-up, which could be explained by the
conversion of the cholecalciferol regime from weekly to
monthly after 2 months in the patients with baseline
25(OH)D deficiency. The activation of vitamin D meta-
bolism, that is, increasing deactivation of active vitamin D
by 24-hydroxlayse following cholecalciferol treatment,31
might also have played a role.
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Vitamin D binding protein is an important transport
protein for both 25(OH)D and 1,25(OH)2D.
32 Previous data
showing a strong positive correlation between uACR and
uVDBPCR in type 1 diabetic patients were consistent with
our results, suggesting that reduction in uVDBPCR along
with uACR might lead to the increase of serum vitamin D
levels by less urine excretion of protein-bound 25(OH)D
and 1,25(OH)2D.
33 In our study uVDBPCR showed a trend
Table 3 | Evolution of vitamin D, uACR, urinary TGF-b1, and MCP-1 in smokers vs nonsmokers
Smokers (n=15) Nonsmokers (n=34)
25(OH)D (ng/ml) (mean±s.d.)
Baseline 16.6±6.0 15.2±7.4
Month 2 43.8±11.4* 40.1±11.4*
Month 4 40.6±9.9* 39.3±14.1*
1,25(OH)2D (pg/ml) (mean±s.d.)
Baseline 16.3±8.7# 27.7±15.1
Month 2 56.9±14.2* 48.4±16.3*
Month 4 57.5±49* 41.2±23.5*
Spot uACR (mg/mmol) (geometric mean (95% CI); median (IQR))
Baseline 21.9 (10.7–45); 14.1 (5.8–90) 14.4 (7.2–28.7); 12.3 (2.7–89.5)
Month 2 18.1 (9–36.3); 19.5 (5.8–57.4) 10.2 (5–20.9); 9.7 (2.2–53.3)*
Month 4 21.1 (9.6–46.6); 26.9 (6.5–70.5) 9.3 (4.6–19.1); 10.9 (1.7–38.5)*
Urinary TGF-b1/creatinine ratio (ng/mmol) (geometric mean (95% CI); median (IQR))
Baseline 23.3 (13.6–40); 19.2 (10.9–59.2) 28 (20.5–38.2); 34.7 (18.6–50.4)
Month 2 19.7 (10.4–37.1); 17.4 (11.7–48.6) 14 (8.7–22.3); 16.7 (8.1–38.2)*
Month 4 15.6 (7.2–33.5); 21.6 (10.2–40.8) 7.5 (4.3–13.2); 5.9 (2.2–27.8)*
Urinary MCP-1/creatinine ratio (ng/mmol) (geometric mean (95% CI); median (IQR))
Baseline 9.4 (6.2–14.3); 9.4 (4.8–16.4) 10.9 (7.4–16.1); 10.6 (7.2–22.2)
Month 2 9.3 (5.7–15.4); 10 (4.0–18.4) 14.5 (11.2–18.8); 13.2 (8.2–22.9)
Month 4 13.9 (8.9–21.8); 12.8 (7.8–23.6) 11.1 (6.8–18); 12.9 (8.7–23.6)
Abbreviations: CI, confidence interval; IQR, interquartile range; MCP-1, monocyte chemoattractant protein-1; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D,
25-hydroxyvitamin D; TGF-b1, transforming growth factor-b1; uACR, urinary albumin-to-creatinine ratio.
*Po0.05 vs baseline; #Po0.05 smokers vs nonsmokers.
Skewed values are presented as geometric mean with 95% CI and median and IQR.
a
c d
b
50 50
40
30
20
10
0
Baseline 2 months 4 months
*
*
*P = 0.0095
vs baseline
+P < 0.0001
vs baseline
*P = 0.1799
vs baseline
+P = 0.4916
vs baseline
*P = 0.2493
vs baseline
+P = 0.6749
vs baseline
*P = 0.0315
vs baseline
+P = 0.0012
vs baseline
+
*
*
+
+
+
G
eo
m
et
ric
 m
ea
n 
of
u
rin
e 
TG
F-
β1
/c
re
at
in
in
e 
ra
tio
(ng
/m
mo
l)
G
eo
m
et
ric
 m
ea
n 
of
u
rin
e 
M
CP
-1
/c
re
at
in
in
e 
ra
tio
(ng
/m
mo
l)
G
eo
m
et
ric
 m
ea
n 
of
u
rin
e 
TG
F-
β1
/c
re
at
in
in
e 
ra
tio
(ng
/m
mo
l)
40
30
20
10
0
30
20
10
0
G
eo
m
et
ric
 m
ea
n 
of
u
rin
e 
M
CP
-1
/c
re
at
in
in
e 
ra
tio
(ng
/m
mo
l)
30
20
10
0
Baseline 2 Months 4 Months
Baseline 2 Months 4 Months Baseline 2 Months 4 Months
Figure 5 | Evolution of urinary cytokines. (a) Urinary transforming growth factor-b1 (TGF-b1)/creatinine ratio at 2- and 4-month follow-up
in the treatment group (n¼ 49) and (b) in the subgroup of patients (n¼ 40) who had no changes of antihypertensive medications.
(c) Urinary monocyte chemoattractant protein-1 (MCP-1)/creatinine ratio at 2- and 4-month follow-up in the treatment group (n¼ 49) and
(d) in the subgroup of patients (n¼ 40) who had no changes of antihypertensive medications. Error bars represent 95% confidence intervals.
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toward a reduction, although it did not reach statistical
significance. Consistently, plasma VDBP increased during the
follow-up. Therefore, at least a marginal effect of reduction in
uVDBPCR on the increase of serum vitamin D levels cannot
be excluded.
The baseline uACR in our study was lower compared with
previous studies.12,14 This may be because of the fact that
vigorous efforts have been made to optimize BP treatment,
including the use of RAAS inhibitors, and diabetic control in
our long-term follow-up patients. However, the uACR
decreased significantly at both 2- and 4-month follow-up.
This effect cannot be explained by any modification of
antihypertensive drugs, as the significant reduction in uACR
was consistent in patients who had no changes of type or
dose of antihypertensive medications, including RAAS inhi-
bition, during the follow-up. The reduction in albuminuria
in our study is consistent with the VITAL study showing the
reduction in albuminuria following treatment with active
vitamin D analog in addition to RAAS inhibition.14 Although
these data are from diabetic patients, this beneficial effect of
cholecalciferol treatment may not be restricted to these
patients, as some previous trials with active vitamin D analogs
were performed in heterogeneous groups of CKD patients.10–12
Urinary TGF-b1/creatinine ratio also showed a significant
reduction at both 2 and 4 months. As TGF-b1 is well known
as a profibrotic cytokine involved in the progression of
CKD,34 its reduction by cholecalciferol in patients on
established RAAS inhibition may indicate an additional
beneficial effect in delaying the progression of CKD. Unlike
our results for urinary TGF-b1, we could not show any
beneficial effect of cholecalciferol in reducing urinary
MCP-1, which is inconsistent with a previous in vivo study.35
To better understand this surprising finding, we reviewed the
cases with higher urinary MCP-1 levels and defined a group
(n¼ 20) with MCP-1/creatinine ratio of 413.7 ng/mmol.
The cutoff was chosen, as it was the median value of MCP-1/
creatinine ratio in patients with macroalbuminuria in our
previous study.30 The analysis in this group showed a trend
toward a reduction during the follow-up period (geometric
mean with 95% confidence interval 25.7 ng/mmol (19.8–33.5)
at baseline; 19.9 ng/mmol (14.1–28.1) at 2 months, P¼ 0.2757;
and 16.2 ng/mmol (8.2–32) at 4 months, P¼ 0.2536), although
it did not reach statistical significance. Therefore, the missing
effect on MCP-1 levels in our study might be explained by the
overall relatively suppressed baseline levels of urinary MCP-1.
Clearly, this hypothesis has to be proved in a larger controlled
clinical trial.
Previous data suggest an adverse effect of smoking on renal
function, although the mechanism is not clear.36,37 Despite
both smokers and nonsmokers showing a significant increase
of both 25(OH)D and 1,25(OH)2D upon cholecalciferol
treatment, there was a significant reduction in uACR and
urinary TGF-b1 only in nonsmokers, suggesting a potential
translation of the negative impact of smoking on CKD with
worse response to a therapy setting based on vitamin D
repletion. However, because of the small sample size, it is not
clear to what extent smoking played a role in this result, and
this needs to be evaluated in a larger controlled trial.
The follow-up of patients with sufficient baseline
25(OH)D at 4 months did not show any significant changes
of all parameters vs baseline. Although the number of
patients was small, this result still supports the potential
beneficial effect of vitamin D repletion.
The ‘non-classical’ effects of vitamin D, which are
unrelated to mineral metabolism, are known to be mediated
by the activation of the VDR.38 There is an increasing body of
evidence that the effect of VDR activation is due, at least in
part, to downregulation of the RAAS. Li et al.39 demonstrated
that renin expression in the kidney and plasma angiotensin II
levels were increased in VDR-null mice compared with wild-
type mice. This finding was confirmed by further experi-
ments using 1,25(OH)2D3 or inhibitors of 1,25(OH)2D3
synthesis in the wild-type mice. The same group further
showed that VDR-null mice developed more severe renal
damage following unilateral ureteral obstruction accompa-
nied by significant induction of extracellular matrix proteins
and profibrogenic and proinflammatory factors such as
TGF-b and MCP-1. These were reversed by the treatment
with losartan, suggesting that activation of VDR attenuates
obstructive renal injury at least in part by suppressing the
RAAS.40 In addition, paricalcitol treatment was shown to
significantly reduce the mRNA levels and protein expression
of angiotensinogen, renin, and renin receptor in subtotally
nephrectomized rats.41 Studies in experimental animal
models were then performed to answer the question whether
combined VDR activation and RAAS inhibition results
in any synergistic effects. Studies in mouse models for
both type 1 (ref. 35) and type 2 (ref. 42) diabetes mellitus
demonstrated that the combined treatment with losartan and
paricalcitol completely prevented albuminuria, suppressed
the induction of fibronectin, TGF-b, and MCP-1, and
reversed the decline of slit diaphragm proteins, leading to
the restored glomerular filtration barrier structure, and
markedly reduced glomerulosclerosis. The combined treat-
ment was significantly more effective compared with
treatment with losartan or paricalcitol alone. The VITAL
study demonstrated the additional antiproteinuric effect of
paricalcitol in diabetic patients on stable treatment of RAAS
inhibition, suggesting the comparable synergistic effect in
patients with DN.14
The remaining question is whether the nutritional
vitamin D supplementation can also exert these nonclassical
effects of VDR activation. Stubbs et al.31 showed in a study
of seven end-stage renal disease patients with minimal renal
1a-hydroxylase activity that 25(OH)D repletion by chole-
calciferol exerts biological effects on circulating mono-
cytes and may alter the inflammatory phenotype of patients
with end-stage renal disease. Together with our data, these
data suggest an effect of cholecalciferol therapy on VDR-
responsive cellular pathways.
There are clear limitations of our study to be discussed.
The study was uncontrolled, the number of patients was
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small, and the follow-up period was short. As the enrollment
and follow-up of the patients were undertaken mostly during
the wintertime, it is not clear whether the effects of vitamin D
repletion by cholecalciferol would be similar in summertime.
It might be that there are less confounding factors in the
evaluation of the effect of cholecalciferol in wintertime, as
25(OH)D levels increase naturally in summertime.43,44
Another limitation is that we were not able to answer the
question whether the cholecalciferol treatment would have
similar effects in patients with sufficient serum 25(OH)D
levels, as we enrolled only patients with low 25(OH)D levels
into cholecalciferol treatment. Previous clinical trials with
paricalcitol12,14 did not specify how many patients were in
replete status of 25(OH)D at the enrollment. In the trial by
Alborizi et al.11 all patients had serum 25(OH)D levels
o30 ng/ml and 43% of patients had a level o10 ng/ml. In
the trial by Fishbane et al.12 the mean serum 25(OH)D value
in the treatment group was 23.6±12.1 ng/ml. The mean
serum 25(OH)D value in VITAL study14 was 16.4±8.4 ng/ml,
which is comparable to that of our treatment group
(15.6±7.0 ng/ml). The number of patients with baseline
25(OH)D value X15 ng/ml was 53% in the VITAL study and
62% in our study. These findings indicate that a significant
proportion of patients had low serum 25(OH)D in the
previous clinical trials. Therefore, the effect of vitamin D
treatment in non-vitamin D-deficient patients needs to be
investigated in further clinical trials. The above-mentioned
limitations are certainly important factors to consider in
further clinical trials involving nutritional vitamin D
supplementation.
CONCLUSION
Cholecalciferol treatment increased both serum 25(OH)D
and 1,25(OH)2D effectively in type 2 diabetic patients with
CKD stage 2–4. The uACR decreased significantly and this
suggests that the vitamin D repletion by cholecalciferol may
have comparable antiproteinuric effects to active vitamin D
analogs. The urinary TGF-b1 decreased significantly, suggest-
ing a potential beneficial effect of vitamin D repletion on
profibrotic urinary cytokines. This is the first study, to our
knowledge, showing these beneficial effects of nutritional
vitamin D supplementation in diabetic patients with CKD
treated with RAAS inhibition. A controlled trial with long-
term follow-up is required to confirm the antiproteinuric and
renoprotective effects of cholecalciferol. If the effectiveness of
cholecalciferol can be demonstrated in a controlled clinical
trial, this may suggest the use of cholecalciferol in addition to
RAAS inhibition to delay the progression of CKD.
MATERIALS AND METHODS
Study design
The study was an open-label prospective observational study.
Patients were recruited from October 2009 to April 2010. The
follow-up period was 4 months and the patients were monitored
at 2 and 4 months. The study protocol was approved by the local
NHS (National Health Service) research ethics committee and all
participants gave informed consent according to the Declaration of
Helsinki Principles.
Study population
All patients attending the diabetic nephropathy clinic at the
Hammersmith Hospital, London, were evaluated for enrollment.
The diagnosis of DN was made by an elevated uACR (430 mg/mmol)
on at least two occasions and the exclusion of other etiologies
for CKD by history, clinical, and laboratory examinations, including
urine sediment and renal ultrasound. Patients were eligible for the
study if they had type 2 diabetes mellitus treated with at least one
antihyperglycemic medication within the 12 months before enroll-
ment, and were on a stable dose (that is, same type and regimen)
of RAAS inhibition for at least 3 months before enrollment. Other
criteria were uACR 430 mg/mmol or history of macroalbuminuria
(that is, previously uACR 430 mg/mmol); eGFR of 15–90 ml/min per
1.73 m2 (calculated by using equation (7) of the Modification of
Diet in Renal Disease (MDRD) study45); serum calcium corrected for
albumin p10 mg/dl; serum phosphate p5.2 mg/dl; HbA1cp12%;
and age 18–70 years. Patients were excluded if they had etiologies of
CKD other than diabetes, poorly controlled hypertension, treatment
with vitamin D or active vitamin D analogs, steroid treatment,
recurrent urinary tract infections, active malignancy, hepatitis B or C,
or human immunodeficiency virus infection.
End points
Primary end points were correlations between vitamin D concen-
trations (25(OH)D and 1,25(OH)2D) and urinary MCP-1, TGF-b1,
and uACR, and the changes in these parameters under vitamin D
repletion using cholecalciferol. Secondary end points were changes
in other laboratory and clinical parameters, including BP, eGFR,
serum calcium corrected for albumin, phosphate, intact parathyroid
hormone, HbA1c, VDBP in plasma and urine, and urine calcium
excretion. In a post hoc analysis, the primary end points were
investigated in the subgroup of smokers.
Intervention
According to our hospital standard management guidelines, vitamin
D deficiency and insufficiency were defined as serum 25(OH)D
p16 ng/ml (40 nmol/l) and 16 ng/ml (40 nmol/l) to 32 ng/ml
(80 nmol/l), respectively. Patients with vitamin D deficiency were
treated with oral cholecalciferol 40,000 units weekly for 8 weeks
(correction phase), and then with the same dose monthly (mainte-
nance phase), and patients with vitamin D insufficiency were treated
with cholecalciferol 40,000 units monthly. Patients with sufficient
vitamin D (serum 25(OH)D 432 ng/ml) did not receive any
cholecalciferol. During the course of the study, antihypertensive
medications could be changed if it was necessary in the view of the
treating physician.
Measurement of outcomes
The baseline data set included the following variables: age, sex,
ethnicity, comorbidity, medication, duration of diabetes, smoking
history, body mass index, BP, vitamin D concentrations (25(OH)D
and 1,25(OH)2D), urinary MCP-1, TGF-b1, uACR, eGFR, serum
albumin, serum calcium corrected for albumin, phosphate, intact
parathyroid hormone, HbA1c, VDBP in plasma and urine, and
urine calcium excretion. Urinary excretion of albumin, TGF-b1,
MCP-1, VDBP, and calcium was measured in single-spot urine
samples and expressed as a ratio to creatinine to account for
different urine volume and concentration states. Urine samples were
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taken between 0930 and 1200 hours in the morning in an
ambulatory setting. Correlation analyses of baseline vitamin D
and urinary MCP-1, TGF-b1, and uACR were performed. After the
treatment was begun with oral cholecalciferol, patients were
monitored at 2 and 4 months and the impact of vitamin D
repletion on urinary MCP-1, TGF-b1, uACR, and other parameters,
including BP, eGFR, serum calcium corrected for albumin, serum
phosphate, intact parathyroid hormone, HbA1c, VDBP in plasma
and urine, and urine calcium excretion, was investigated.
The definition of compliance included both medication
compliance and follow-up protocol compliance. Medication com-
pliance was evaluated by the review of all drugs and their dosing,
including regular and investigational drugs in each patient during
each visit.
Analysis of vitamin D
Serum 25(OH)D was measured by in-house liquid chromato-
graphy–tandem mass spectrometry assay and serum 1,25(OH)2D
was measured by manual radioimmunoassay involving a chromato-
graphic extraction step (Diasorin, Saluggia, Italy).
Analysis of urinary MCP-1 and TGF-b1 and VDBP in plasma
and urine
Spot urine samples were collected in the outpatient clinic between
0930 and 1200 hours in the morning and centrifuged immediately
and supernatants were stored in a –80 1C freezer. Only urine samples
free from bacterial growth and significant leukocyte counts (o10
white blood cell count/high-power field) were further analyzed.
Urinary MCP-1 and TGF-b1 were measured by specific enzyme-
linked immunosorbent assay (ELISA) using commercially available
paired antibodies (R&D Systems, Abingdon, UK) according to the
manufacturer’s instructions. The sensitivity of the MCP-1 ELISA
and TGF-b1 ELISA was 9.8 and 7.8 pg/ml, respectively. VDBP was
measured by specific ELISA using commercially available Quanti-
kine ELISA kit (R&D Systems). The sensitivity was 15.6 ng/ml.
Statistical analysis
Continuous variables with normal distribution were reported as
mean±s.d. Skewed variables were log-transformed for the statistical
analyses and reported as both geometric mean values with 95%
confidence interval and median with interquartile range. For the
values below the minimum detectable limit (ACR, 6 out of 160
measurements; urinary TGF-b1, 6 out of 160 measurements; and
urinary MCP-1, 2 out of 160 measurements), median values between
0 and the minimum detection limit were used. Associations between
parameters were measured using Pearson’s correlation coefficient.
Differences between two time points for continuous variables were
analyzed using paired t-test. All probabilities were two tailed. The
P-values o0.05 were considered significant. Statistical analyses were
performed using Prism 5.0 (GraphPad, Software, La Jolla, CA).
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